Semaglutide, the active ingredient in Ozempic and Wegovy, has become one of the most prescribed drugs in the United States. Between 2022 and early 2025, a severe national shortage of brand-name semaglutide created a window in which compounding pharmacies could legally produce their own versions. That window has now largely closed — but the market for compounded semaglutide has not disappeared. The result is a regulatory landscape in 2026 that is confusing, legally contested, and potentially dangerous for consumers who do not understand the distinctions.
This guide examines where things stand as of April 2026, what the FDA has communicated, and what the available evidence says about the safety of compounded semaglutide products.
The Shortage List and Why It Matters
Federal law generally prohibits compounding pharmacies from producing copies of commercially available FDA-approved drugs. One important exception exists: when the FDA places a drug on its official Drug Shortage List, compounders may produce versions of that drug to fill the gap in supply. This is the legal mechanism that allowed compounded semaglutide to exist at scale.
On February 21, 2025, the FDA updated its Drug Shortage List and declared that the shortage of all doses of injectable semaglutide — both Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management) — had been resolved. With supply normalized, the primary legal justification for most compounded semaglutide production ended.
The FDA did not require an immediate stop. Instead, it announced phased enforcement timelines: 503A compounding pharmacies received until April 22, 2025, and 503B outsourcing facilities received until May 22, 2025, to wind down their semaglutide compounding operations. The stated goal was to avoid abruptly interrupting patient treatment.
503A vs. 503B: Two Different Types of Compounding Pharmacy
Not all compounding pharmacies operate under the same regulatory framework. Understanding the distinction between 503A and 503B pharmacies is essential to evaluating what is and is not legal in 2026.
Section 503A Pharmacies
503A pharmacies are traditional compounding pharmacies that produce medications for individual patients based on a specific prescription from a licensed prescriber. They operate under state pharmacy board oversight and are exempt from certain federal manufacturing requirements — but only when they meet a set of conditions, including that the compounded product is not "essentially a copy" of a commercially available drug.
There is a narrow exception: a prescriber may determine that a compounded product offers a "clinically significant difference" for a specific patient — for example, a different formulation for a patient with a documented allergy to an inactive ingredient in the brand-name version. Under 503A, this determination must be made and documented by the prescribing practitioner on a patient-by-patient basis.
Section 503B Outsourcing Facilities
503B outsourcing facilities are registered with the FDA, subject to federal inspections, and may produce compounded drugs in larger quantities without patient-specific prescriptions. They function more like small-scale manufacturers. When semaglutide was on the shortage list, 503B facilities could produce it at volume. With the shortage resolved and semaglutide not appearing on the FDA's 503B Bulks List, these facilities have lost their primary legal basis for compounding it.
The practical difference: 503A pharmacies may still have a narrow path to compound semaglutide for specific patients with documented clinical need. 503B facilities, for the most part, may not.
The Salt Form Problem
One of the more consequential safety issues that has emerged involves the chemical form of semaglutide being used by some compounders. The FDA-approved products (Ozempic and Wegovy) use semaglutide base — the free-base form of the molecule. However, the FDA has identified compounded products containing semaglutide sodium or semaglutide acetate — salt forms that are chemically distinct active ingredients.
The FDA has stated that it does not have evidence these salt forms share the same pharmacological properties as the base form used in approved drugs. Critically, the agency has also stated that it is not aware of a lawful basis for using these salt forms in compounding, because they are not components of any FDA-approved drug product. Products compounded with semaglutide sodium or semaglutide acetate have not been evaluated for safety or efficacy.
For consumers, this means a compounded product labeled "semaglutide" may not contain the same molecule that was studied in the clinical trials supporting Ozempic and Wegovy. The distinction between base forms and salt forms is not typically visible to patients and may not be disclosed clearly at the point of sale.
The Combination Product Workaround
After the shortage ended, some compounders began formulating semaglutide in combination with other ingredients — most commonly cyanocobalamin (vitamin B12) — arguing that the resulting product is not "essentially a copy" of the commercially available drug because it contains an additional active ingredient.
The FDA addressed this approach directly. On April 1, 2026, the agency issued a statement reminding compounders that the statutory exemptions under the FD&C Act only apply when all applicable conditions are met. The FDA's position is that adding a minor ingredient like B12 does not automatically create a meaningfully different product, and compounders relying on this theory may still be producing what the agency considers an unauthorized copy of an approved drug.
The legal status of this approach remains contested. Multiple lawsuits — filed by compounding pharmacies, telehealth companies, and industry associations — have challenged the FDA's enforcement authority, and several federal courts have issued injunctions that complicate the regulatory picture. As of April 2026, the legal battle is ongoing, and the outcome may vary by jurisdiction.
Safety Concerns: What the Evidence Shows
The safety profile of FDA-approved semaglutide (Ozempic, Wegovy) is well established through extensive clinical trials. Compounded semaglutide, by contrast, has not undergone the same level of scrutiny. Several categories of concern have emerged.
Potency and Dosing Inconsistency
A 2024 study examining compounded semaglutide from unregulated online sellers found that only approximately 30 percent of samples met quality standards. Dosage strengths in tested products ranged from roughly 0.4 percent to 302 percent of labeled concentrations — a spread that is clinically alarming. Underdosed products may be therapeutically ineffective. Overdosed products may cause severe gastrointestinal distress, dangerous blood sugar fluctuations, or other adverse events.
Impurities and Contamination
The FDA has reported that semaglutide active pharmaceutical ingredients (APIs) sourced from certain importers — even some on the FDA's green list — have shown high impurity levels. Between 2024 and 2025, the agency documented serious adverse events linked to contaminated compounded batches, including infections requiring hospitalization attributed to inadequately regulated manufacturing conditions.
Sterility Failures
Injectable products carry inherent sterility requirements. The FDA has issued more than 30 warning letters to compounders in early 2026, with citations including inadequate sterile compounding practices, failure to conduct adequate potency testing, and manufacturing conditions that do not meet Current Good Manufacturing Practice (cGMP) standards.
Key point: The safety data supporting semaglutide comes from clinical trials using the specific formulation manufactured by Novo Nordisk under FDA oversight. A compounded product labeled "semaglutide" — even if it contains the correct molecule at the correct concentration — has not been manufactured, tested, or verified to the same standard.
How to Evaluate a Compounding Pharmacy
If you and your prescriber determine that a compounded formulation is appropriate for your specific clinical situation, several steps may help reduce — though not eliminate — risk.
- Check NABP accreditation. The National Association of Boards of Pharmacy maintains a Compounding Pharmacy Accreditation program. NABP accreditation is a three-year credential that indicates the pharmacy has been evaluated against compounding safety standards. You can verify accreditation status through the NABP website.
- Look for PCAB accreditation. The Pharmacy Compounding Accreditation Board (now administered by the Accreditation Commission for Health Care, or ACHC) provides accreditation that includes on-site surveys by independent experts and annual compliance verification against USP 795 (non-sterile compounding) and USP 797 (sterile compounding) standards.
- Verify state licensing. Every state pharmacy board maintains a list of licensed pharmacies. Confirm the pharmacy holds an active, unrestricted license in the state where it operates.
- Ask about third-party potency testing. A reputable compounding pharmacy should be able to provide certificates of analysis (COAs) from independent laboratories verifying the identity, potency, and sterility of their compounded products. If a pharmacy cannot or will not provide this documentation, that is a significant red flag.
- Confirm the prescriber relationship. Under 503A, a valid patient-specific prescription is required. If a provider is willing to prescribe compounded semaglutide without a meaningful clinical evaluation — or if the product is available without any prescription at all — the operation may not be compliant with federal or state law.
Cost: Brand-Name vs. Compounded
Cost has been a primary driver of demand for compounded semaglutide. The price gap is substantial.
Brand-name semaglutide carries a list price of approximately $900 to $1,000 per month for Ozempic and $1,300 to $1,400 per month for Wegovy without insurance. Annual out-of-pocket costs for uninsured patients may exceed $12,000. Insurance coverage for weight management indications remains inconsistent — many plans cover Ozempic for type 2 diabetes but do not cover Wegovy for obesity.
Compounded semaglutide, when available through telehealth providers and compounding pharmacies, has typically cost between $129 and $299 per month — representing 70 to 80 percent savings compared to brand-name options.
However, the regulatory changes described above mean that access to compounded semaglutide has become significantly more restricted. Patients who were previously obtaining compounded versions may find that their provider can no longer legally supply it, or that the legal basis for the prescription has narrowed considerably.
It is also worth noting that Novo Nordisk has taken steps to improve affordability of its branded products, including savings programs and partnerships with certain pharmacies and insurers. Whether those measures meaningfully close the gap for uninsured or underinsured patients remains a matter of debate.
The Legal Gray Zone in April 2026
The regulatory status of compounded semaglutide in April 2026 is genuinely ambiguous. Multiple federal court rulings have issued injunctions that prevent the FDA from fully enforcing its post-shortage compounding restrictions in certain jurisdictions. Industry lawsuits challenging the FDA's interpretation of the "essentially a copy" standard are working through the courts. State-level regulations add another layer of complexity, as some states have taken more permissive positions than the federal framework.
For consumers, the practical reality is this: compounded semaglutide is still being produced and sold in some parts of the country, through some pharmacies and telehealth platforms. Whether any given product is being produced on a fully legal basis depends on the specific pharmacy's regulatory status (503A vs. 503B), the state in which it operates, the applicable court orders, and the clinical documentation supporting the prescription.
This is not a situation where there is a clear, universal answer to the question of whether compounded semaglutide is "legal." The answer depends on specific facts that vary by provider, patient, and jurisdiction.
What This Means Going Forward
Several developments may reshape this landscape in the coming months. The FDA has signaled continued enforcement activity, including additional warning letters and potential injunctive actions against compounders that the agency believes are operating outside the law. Court decisions in pending cases may clarify or further complicate the regulatory framework. And the emergence of next-generation GLP-1 receptor agonists — including oral formulations and dual- or triple-agonist compounds — may gradually reduce the market pressure that drove the compounded semaglutide industry in the first place.
For individuals currently using or considering compounded semaglutide, the most important steps are to work with a licensed healthcare provider who understands the current regulatory environment, to verify the credentials and accreditation of any compounding pharmacy, and to understand that a compounded product — regardless of its label — has not been manufactured or tested to the same standard as an FDA-approved drug.
This article is for informational purposes only and does not constitute medical or legal advice. The regulatory landscape described here is evolving rapidly, and specific legal questions should be directed to a qualified attorney. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.